Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma

Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors. However, a limitation to such treatment is the occurrence of resistance. Tackling the adaptive changes helping cells survi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Belleudi, Francesca, Noto, Alessia, De Vitis, Claudia, Pisanu, Maria Elena, Coluccia, Pierpaolo, Camerlingo, Rosa, Roscilli, Giuseppe, Ribas, Antoni, Di Napoli, Arianna, Torrisi, Maria Rosaria, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Mancini, Rita, Ciliberto, Gennaro
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694796/
https://ncbi.nlm.nih.gov/pubmed/26208478
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares